Safety evaluation of bi‐layered allogenic keratinocyte and fibroblast skin substitute for diabetic foot ulcers—SAFESKIN‐DFU: A Phase 1 clinical trial

Shayan Farzanbakhsh,Mohammad Reza Amini,Hoda Madani,Bahareh Sadri,Seyedeh Nafiseh Hassani,Nasrin Fallah,Azam Samadian,Raheleh Aghdami,Zahra Khalajasadi,Hossein Baharvand,Massoud Vosough,Ensiyeh Hajizadeh‐Saffar
DOI: https://doi.org/10.1111/dom.15843
2024-08-21
Diabetes Obesity and Metabolism
Abstract:Aim To assess the safety and efficacy of a local skin substitute product in the treatment of chronic diabetic foot ulcers (DFUs). Materials and Methods Five patients were evaluated over 6 months. Skin substitutes were applied twice at 2‐week intervals. Patients were monitored for any possible adverse effects and wound improvement. Results The results indicated the overall safety of the skin substitute, with only few adverse effects unrelated to this product. Significant reduction in wound size was observed in four patients during the initial 12‐week treatment phase, with complete closure in two patients at 24 weeks. Conclusions The application of a bi‐layered allogeneic keratinocyte and fibroblast skin substitute in patients with chronic DFU was safe and associated with favourable wound healing results. Adherence to standard treatment protocols, including optimal offloading, is essential to maximize the likelihood of successful wound healing.
endocrinology & metabolism
What problem does this paper attempt to address?